These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30653533)

  • 1. Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome.
    Hessl D; Harvey D; Sansone S; Crestodina C; Chin J; Joshi R; Hagerman RJ; Berry-Kravis E
    PLoS One; 2019; 14(1):e0209984. PubMed ID: 30653533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
    Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
    Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of mavoglurant and its potential for the treatment of fragile X syndrome.
    Gomez-Mancilla B; Berry-Kravis E; Hagerman R; von Raison F; Apostol G; Ufer M; Gasparini F; Jacquemont S
    Expert Opin Investig Drugs; 2014 Jan; 23(1):125-34. PubMed ID: 24251408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents.
    Hagerman R; Jacquemont S; Berry-Kravis E; Des Portes V; Stanfield A; Koumaras B; Rosenkranz G; Murgia A; Wolf C; Apostol G; von Raison F
    Sci Rep; 2018 Nov; 8(1):16970. PubMed ID: 30451888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.
    Pop AS; Levenga J; de Esch CE; Buijsen RA; Nieuwenhuizen IM; Li T; Isaacs A; Gasparini F; Oostra BA; Willemsen R
    Psychopharmacology (Berl); 2014 Mar; 231(6):1227-35. PubMed ID: 23254376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice.
    Zerbi V; Markicevic M; Gasparini F; Schroeter A; Rudin M; Wenderoth N
    Neuroimage; 2019 May; 191():392-402. PubMed ID: 30807820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
    Youssef EA; Berry-Kravis E; Czech C; Hagerman RJ; Hessl D; Wong CY; Rabbia M; Deptula D; John A; Kinch R; Drewitt P; Lindemann L; Marcinowski M; Langland R; Horn C; Fontoura P; Santarelli L; Quiroz JA;
    Neuropsychopharmacology; 2018 Feb; 43(3):503-512. PubMed ID: 28816242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.
    Pop AS; Gomez-Mancilla B; Neri G; Willemsen R; Gasparini F
    Psychopharmacology (Berl); 2014 Mar; 231(6):1217-26. PubMed ID: 24232444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
    Gantois I; Pop AS; de Esch CE; Buijsen RA; Pooters T; Gomez-Mancilla B; Gasparini F; Oostra BA; D'Hooge R; Willemsen R
    Behav Brain Res; 2013 Feb; 239():72-9. PubMed ID: 23142366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization.
    Vranesic I; Ofner S; Flor PJ; Bilbe G; Bouhelal R; Enz A; Desrayaud S; McAllister K; Kuhn R; Gasparini F
    Bioorg Med Chem; 2014 Nov; 22(21):5790-803. PubMed ID: 25316499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
    Rutrick D; Stein DJ; Subramanian G; Smith B; Fava M; Hasler G; Cha JH; Gasparini F; Donchev T; Ocwieja M; Johns D; Gomez-Mancilla B
    Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
    Jacquemont S; Curie A; des Portes V; Torrioli MG; Berry-Kravis E; Hagerman RJ; Ramos FJ; Cornish K; He Y; Paulding C; Neri G; Chen F; Hadjikhani N; Martinet D; Meyer J; Beckmann JS; Delange K; Brun A; Bussy G; Gasparini F; Hilse T; Floesser A; Branson J; Bilbe G; Johns D; Gomez-Mancilla B
    Sci Transl Med; 2011 Jan; 3(64):64ra1. PubMed ID: 21209411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.
    Scharf SH; Jaeschke G; Wettstein JG; Lindemann L
    Curr Opin Pharmacol; 2015 Feb; 20():124-34. PubMed ID: 25488569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief report: Visual processing of faces in individuals with fragile X syndrome: an eye tracking study.
    Farzin F; Rivera SM; Hessl D
    J Autism Dev Disord; 2009 Jun; 39(6):946-52. PubMed ID: 19399604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.
    Rouzade-Dominguez ML; Pezous N; David OJ; Tutuian R; Bruley des Varannes S; Tack J; Malfertheiner P; Allescher HD; Ufer M; Rühl A
    Neurogastroenterol Motil; 2017 Aug; 29(8):. PubMed ID: 28337838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study.
    Hong MP; Eckert EM; Pedapati EV; Shaffer RC; Dominick KC; Wink LK; Sweeney JA; Erickson CA
    J Neurodev Disord; 2019 Jan; 11(1):1. PubMed ID: 30665413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of AFQ056 on language learning in fragile X syndrome.
    Berry-Kravis E; Abbeduto L; Hagerman R; Coffey CS; Cudkowicz M; Erickson CA; McDuffie A; Hessl D; Ethridge L; Tassone F; Kaufmann WE; Friedmann K; Bullard L; Hoffmann A; Veenstra-VanderWeele J; Staley K; Klements D; Moshinsky M; Harkey B; Long J; Fedler J; Klingner E; Ecklund D; Costigan M; Huff T; Pearson B;
    J Clin Invest; 2023 Aug; 134(5):. PubMed ID: 37651202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral Expression of Metabotropic Glutamate Receptor Subtype 5 in Idiopathic Autism Spectrum Disorder and Fragile X Syndrome: A Pilot Study.
    Brašić JR; Nandi A; Russell DS; Jennings D; Barret O; Martin SD; Slifer K; Sedlak T; Seibyl JP; Wong DF; Budimirovic DB
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test.
    de Esch CE; van den Berg WE; Buijsen RA; Jaafar IA; Nieuwenhuizen-Bakker IM; Gasparini F; Kushner SA; Willemsen R
    Neurobiol Dis; 2015 Mar; 75():31-9. PubMed ID: 25562659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue of Fmr1
    Westmark PR; Dekundy A; Gravius A; Danysz W; Westmark CJ
    Neurobiol Dis; 2018 Nov; 119():190-198. PubMed ID: 30125640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.